Prevention and treatment of HIV infection in neonates: evidence base for existing WHO dosing recommendations and implementation considerations

References

• Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf. Accessed 2016 Dec 29
   Google Scholar
• Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS clinical trials group protocol 076 study group. N Engl J Med. 1994 Nov 03;331(18):1173–1180. PubMed PMID: 7935654; eng. DOI:10.1056/NEJM199411033311801
   PubMed Web of Science ®Google Scholar
• Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med. 2012 Jun 21;366(25):2368–2379. PubMed PMID: 22716975; PubMed Central PMCID: PMC3590113. eng. DOI:10.1056/NEJMoa1108275
   PubMed Web of Science ®Google Scholar
• Fowler MG, Coovadia H, Herron CM, et al. Efficacy and safety of an extended nevirapine regimen in infants of breastfeeding mothers with HIV-1 infection for prevention of HIV-1 transmission (HPTN 046): 18-month results of a randomized, double-blind, placebo-controlled trial. J Acquir Immune Defic Syndr. 2014 Mar 01;65(3):366–374. PubMed PMID: 24189151; PubMed Central PMCID: PMC3945386. eng. DOI:10.1097/QAI.0000000000000052
   PubMed Web of Science ®Google Scholar
• World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach. Second edition. 2016. http://apps.who.int/iris/bitstream/10665/208825/1/9789241549684_eng.pdf?ua=1.
   Google Scholar
• Joint United Nations Agency on HIV/AIDS. Global AIDS update 2016. http://www.unaids.org/en/resources/documents/2016/Global-AIDS-update-2016 (accessed 2016 Jul 22nd) [Internet].
   Google Scholar
• Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008 Nov 20;359(21):2233–2244. PubMed PMID: 19020325; PubMed Central PMCID: PMC2950021. eng. DOI:10.1056/NEJMoa0800971
   PubMed Web of Science ®Google Scholar
• Newell ML, Coovadia H, Cortina-Borja M, et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis [Research support, U.S. Gov’t, P.H.S.]. Lancet. 2004 Oct 2–8;364(9441):1236–1243. PubMed PMID: 15464184; eng. DOI:10.1016/S0140-6736(04)17140-7
   PubMed Web of Science ®Google Scholar
• UNICEF. For every child, end AIDS. Seventh Stocktaking Report. https://data.unicef.org/resources/every-child-end-aids-seventh-stocktaking-report-2016/ (accessed 2017 Jul 1
   Google Scholar
• Luzuriaga K, Tabak B, Garber M, et al. HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment. J Infect Dis. 2014 Nov 15;210(10):1529–1538. PubMed PMID: 24850788; PubMed Central PMCID: PMC4215073. eng. DOI:10.1093/infdis/jiu297
   PubMed Web of Science ®Google Scholar
• Panel on antiretroviral therapy and medical management of HIV-infected children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf. Accessed 2016 Sept 1
   Google Scholar
• Smits A, Annaert P, Allegaert K. Drug disposition and clinical practice in neonates: cross talk between developmental physiology and pharmacology. Int J Pharm. 2013 Aug 16;452(1–2):8–13. PubMed PMID: 22504091; eng.
   PubMed Web of Science ®Google Scholar
• Cotton MF, Holgate S, Nelson A, et al. The last and first frontier–emerging challenges for HIV treatment and prevention in the first week of life with emphasis on premature and low birth weight infants. J Int AIDS Soc . 2015;18(Suppl 6):20271. PubMed PMID: 26639118; PubMed Central PMCID: PMC4670832. eng. DOI:10.7448/IAS.18.7.20271.
   PubMed Web of Science ®Google Scholar
• Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology–drug disposition, action, and therapy in infants and children. N Engl J Med. 2003 Sep 18;349(12):1157–1167. PubMed PMID: 13679531; eng. DOI:10.1056/NEJMra035092
   PubMed Web of Science ®Google Scholar
• Collins JM, Unadkat JD. Clinical pharmacokinetics of zidovudine. An overview of current data [Review]. Clin Pharmacokinet. 1989 Jul;17(1):1–9. PubMed PMID: 2663302; eng. DOI:10.2165/00003088-198917010-00001.
   PubMed Web of Science ®Google Scholar
• Boucher FD, Modlin JF, Weller S, et al. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J Pediatr. 1993 Jan;122(1):137–144. PubMed PMID: 8419601; eng.
   PubMed Web of Science ®Google Scholar
• Mirochnick M, Capparelli E, Connor J. Pharmacokinetics of zidovudine in infants: a population analysis across studies [Research support, U.S. Gov’t, P.H.S.]. Clin Pharmacol Ther. 1999 Jul;66(1):16–24. PubMed PMID: 10430105; eng. DOI:10.1016/S0009-9236(99)70049-4.
   PubMed Web of Science ®Google Scholar
• Moodley D, Pillay K, Naidoo K, et al. Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours [clinical trial]. J Clin Pharmacol. 2001 Jul;41(7):732–741. PubMed PMID: 11452705; eng.
   PubMed Web of Science ®Google Scholar
• Kinai E, Kato S, Hosokawa S, et al. High plasma concentrations of zidovudine (AZT) do not parallel intracellular concentrations of AZT-triphosphates in infants during prevention of mother-to-child HIV-1 transmission. J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):246–253. PubMed PMID: 26859826; eng. DOI:10.1097/QAI.0000000000000950
   PubMed Web of Science ®Google Scholar
• Fillekes Q, Kendall L, Kitaka S, et al. Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children. Pediatr Infect Dis J. 2014 May;33(5):495–498. PubMed PMID: 24736440; PubMed Central PMCID: PMC3990384. eng. DOI:10.1097/INF.0000000000000143
   PubMed Web of Science ®Google Scholar
• Capparelli EV, Mirochnick M, Dankner WM, et al. Pharmacokinetics and tolerance of zidovudine in preterm infants. J Pediatr. 2003 Jan;142(1):47–52. PubMed PMID: 12520254; eng.
   PubMed Web of Science ®Google Scholar
• Balis FM, Pizzo PA, Murphy RF, et al. The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann Inter Med. 1989 Feb 15;110(4):279–285. PubMed PMID: 2643914; eng.
   PubMed Web of Science ®Google Scholar
• Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. Jama. 2001 Apr 25;285(16):2083–2093. PubMed PMID: 11311097; eng.
   PubMed Web of Science ®Google Scholar
• Perry CM, Faulds D. Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs. 1997 Apr;53(4):657–680. PubMed PMID: 9098665; eng.
   PubMed Web of Science ®Google Scholar
• Barry M, Mulcahy F, Merry C, et al. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet. 1999 Apr;36(4):289–304. PubMed PMID: 10320951; eng.
   PubMed Web of Science ®Google Scholar
• Moore KH, Yuen GJ, Raasch RH, et al. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin Pharmacol Ther. 1996 May;59(5):550–558. PubMed PMID: 8646826; eng.
   PubMed Web of Science ®Google Scholar
• Moore KH, Barrett JE, Shaw S, et al. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. Aids. 1999 Nov 12;13(16):2239–2250. PubMed PMID: 10563709; eng.
   PubMed Web of Science ®Google Scholar
• Tremoulet AH, Capparelli EV, Patel P, et al. Population pharmacokinetics of Lamivudine in human immunodeficiency virus-exposed and -infected infants. Antimicrob Agents Chemother. 2007 Dec;51(12):4297–4302. PubMed PMID: 17893155; eng.
   PubMed Web of Science ®Google Scholar
• Tremoulet AH, Nikanjam M, Cressey TR, et al. Developmental pharmacokinetic changes of Lamivudine in infants and children. J Clin Pharmacol. 2012 Dec;52(12):1824–1832. PubMed PMID: 22180560; PubMed Central PMCID: PMC3369109. eng. DOI:10.1177/0091270011426563
   PubMed Web of Science ®Google Scholar
• Chadwick EG, Capparelli EV, Yogev R, et al. Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results. Aids. 2008 Jan 11;22(2):249–255. PubMed PMID: 18097227; eng. DOI:10.1097/QAD.0b013e3282f2be1d
   PubMed Web of Science ®Google Scholar
• Sham HL, Kempf DJ, Molla A, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease [clinical trial]. Antimicrob Agents Chemother. 1998 Dec;42(12):3218–3224. PubMed PMID: 9835517; PubMed Central PMCID: PMC106025. eng.
   PubMed Web of Science ®Google Scholar
• Nikanjam M, Chadwick EG, Robbins B, et al. Assessment of lopinavir pharmacokinetics with respect to developmental changes in infants and the impact on weight band-based dosing [Research support, N.I.H., Extramural].. Clin Pharmacol Ther. 2012 Feb;91(2):243–249. PubMed PMID: 22190064; PubMed Central PMCID: PMC3356582. eng. DOI:10.1038/clpt.2011.218
   PubMed Web of Science ®Google Scholar
• Gulati A, Boudinot FD, Gerk PM. Binding of lopinavir to human alpha1-acid glycoprotein and serum albumin. Drug Metab Dispos. 2009 Aug;37(8):1572–1575. PubMed PMID: 19439488; PubMed Central PMCID: PMC2712434. eng. DOI:10.1124/dmd.109.026708.
   PubMed Web of Science ®Google Scholar
• Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. Aids. 2006 Oct 03;20(15):1931–1939. PubMed PMID: 16988514; eng. DOI:10.1097/01.aids.0000247114.43714.90
   PubMed Web of Science ®Google Scholar
• Jullien V, Urien S, Hirt D, et al. Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years [Research support, Non-U.S. Gov’t]. Antimicrob Agents Chemother. 2006 Nov;50(11):3548–3555. PubMed PMID: 16940058; PubMed Central PMCID: PMC1635168. eng. DOI:10.1128/AAC.00943-05
   PubMed Web of Science ®Google Scholar
• Urien S, Firtion G, Anderson ST, et al. Lopinavir/ritonavir population pharmacokinetics in neonates and infants [Research support, non-U.S. Gov’t]. Br J Clin Pharmacol. 2011 Jun;71(6):956–960. PubMed PMID: 21564164; PubMed Central PMCID: PMC3099384. eng. DOI:10.1111/j.1365-2125.2011.03926.x
   PubMed Web of Science ®Google Scholar
• Saez-Llorens X, Violari A, Deetz CO, et al. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2003 Mar;22(3):216–224. PubMed PMID: 12634581; eng. DOI:10.1097/01.inf.0000055061.97567.34
   PubMed Web of Science ®Google Scholar
• Bouazza N, Foissac F, Fauchet F, et al. Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations [Research Support, Non-U.S. Gov’t]. Antiviral Therapy. 2015;20(2):225–233. PubMed PMID: 25279808; eng. DOI:10.3851/IMP2876
   PubMed Web of Science ®Google Scholar
• La Porte CJ, Back DL, Blanchard T, et al. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Rev Antiviral Ther. 2006;3:4–14.
   Google Scholar
• Zhang C, Denti P, Decloedt EH, et al. Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin. Br J Clin Pharmacol. 2013 Nov;76(5):741–751. PubMed PMID: 23432610; PubMed Central PMCID: PMC3853533. eng. DOI:10.1111/bcp.12101
   PubMed Web of Science ®Google Scholar
• McIlleron H, Ren Y, Nuttall J, et al. Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis. Antiviral Therapy. 2011;16(3):417–421. PubMed PMID: 21555825; eng. DOI:10.3851/IMP1757
   PubMed Web of Science ®Google Scholar
• Holgate SL, Rabie H, Smith P, et al. Trough lopinavir concentrations in preterm HIV-infected infants. Pediatr Infect Dis J. 2012 Jun;31(6):602–604. PubMed PMID: 22414907; eng. DOI:10.1097/INF.0b013e31825046ae
   PubMed Web of Science ®Google Scholar
• Boxwell D, K. Cao, Lewis L, et al. Neonatal toxicity of kaletra oral solution—LPV, ethanol, or propylene glycol?- Abstract #708. Presented at: 18th Conference on Retroviruses and Opportunistic Infections. 2011. Boston, MA.
   Google Scholar
• Musiime V, Fillekes Q, Kekitiinwa A, et al. The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in African HIV-infected children. J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):148–154. PubMed PMID: 24828266; eng. DOI:10.1097/QAI.0000000000000135
   PubMed Web of Science ®Google Scholar
• Viramune. Viramune tablets, oral suspension, package insert labeling. Ridgefield: Boehringer-Ingelheim Pharmaceuticals Inc. Conn FDA Approved 1996 Revised: 01/2014. [cited 2017 Oct 11].
   Google Scholar
• Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet.. 1999 Sep 04;354(9181):795–802. PubMed PMID: 10485720; eng. DOI:10.1016/S0140-6736(99)80008-7
   PubMed Web of Science ®Google Scholar
• Mirochnick M, Capparelli EV, K. N, et al., editors. Nevirapine pharmacokinetics during the first year of life: a population analysis across studies. Pediatric Academic Societies Meeting.; 2006; San Francisco, CA.
   Google Scholar
• Mirochnick M, Fenton T, Gagnier P, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS clinical trials group protocol 250 team. J Infect Dis. 1998 Aug;178(2):368–374. PubMed PMID: 9697716.
   PubMed Web of Science ®Google Scholar
• Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004 Jul 15;351(3):217–228. PubMed PMID: 15247338; eng. DOI:10.1056/NEJMoa033500
   PubMed Web of Science ®Google Scholar
• Coovadia HM, Brown ER, Fowler MG, et al. Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. Lancet. 2012 Jan 21;379(9812):221–228. PubMed PMID: 22196945; PubMed Central PMCID: PMC3539769. eng. DOI:10.1016/S0140-6736(11)61653-X
   PubMed Web of Science ®Google Scholar
• De Waal R, Kroon SM, Holgate SL, et al. Nevirapine concentrations in preterm and low birth weight HIV-exposed infants: implications for dosing recommendations. Pediatr Infect Dis J. 2014 Dec;33(12):1231–1233. PubMed PMID: 24945881.. DOI:10.1097/INF.0000000000000453
   PubMed Web of Science ®Google Scholar
• Taha T, Flynn P, Cababasay M, et al., editors. Comparing maternal triple antiretrovirals (mART) and infant nevirapine (iNVP) prophylaxis for the prevention of mother-to-child transmission (MTCT) of HIV during breastfeeding (BF. 21st International AIDS Conference (AIDS 2016); 2016; Durban, South Africa.
   Google Scholar
• Mirochnick M, Capparelli E, Nielsen K, et al., editors. Nevirapine dosing for treatment in the first month of life. Conference on Retroviruses and Opportunistic Infections (CROI); 2016; Boston, MA, USA, February 22–25, 2016.
   Google Scholar
• Cressey TR, Punyawudho B, Le Coeur S, et al. Assessment of nevirapine prophylactic and therapeutic dosing regimens for neonates. J Acquir Immune Defic Syndr. 2017 Aug 15;75(5):554–560. PubMed PMID: 28489732; PubMed Central PMCID: PMC5508655. eng. DOI:10.1097/QAI.0000000000001447
   PubMed Web of Science ®Google Scholar
• Bolaris MA, Keller MA, Robbins BL, et al. Nevirapine plasma concentrations in human immunodeficiency virus-exposed neonates receiving high-dose nevirapine prophylaxis as part of 3-drug regimen. J Pediatric Infect Dis Soc. 2016 Jan 23:piv084 PubMed PMID: 26803329. DOI:10.1093/jpids/piv084.
   Web of Science ®Google Scholar
• Capparelli EV, Rossi S, Maswabi K, et al., editors. Nevirapine (NVP) concentrations in HIV infected newborns receiving therapeutic dosing. Conference on Retroviruses and Opportunistic Infections (CROI); 2016; February 22–25, 2016, Boston, Massachusetts.
   Google Scholar
• Iwamoto M, Wenning LA, Petry AS, et al. Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects. Clin Pharmacol Ther. 2008 Feb;83(2):293–299. PubMed PMID: 17713476. DOI:10.1038/sj.clpt.6100281
   PubMed Web of Science ®Google Scholar
• Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos. 2007 Sep;35(9):1657–1663. DOI: dmd.107.016196[pii]10.1124/dmd.107.016196 PubMed PMID: 17591678; eng.
   PubMed Web of Science ®Google Scholar
• Bosma PJ, Seppen J, Goldhoorn B, et al. Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem. 1994 Jul 8;269(27):17960–17964. PubMed PMID: 8027054; eng.
   PubMed Web of Science ®Google Scholar
• Onishi S, Kawade N, Itoh S, et al. Postnatal development of uridine diphosphate glucuronyltransferase activity towards bilirubin and 2-aminophenol in human liver. Biochem J. 1979 Dec 15;184(3):705–707. PubMed PMID: 120201; PubMed Central PMCID: PMC1161858. eng.
   PubMed Web of Science ®Google Scholar
• Clarke DF, Acosta EP, Rizk ML, et al. Raltegravir pharmacokinetics in neonates following maternal dosing. J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):310–315. PubMed PMID: 25162819; PubMed Central PMCID: PMC4197108. eng. DOI:10.1097/QAI.0000000000000316
   PubMed Web of Science ®Google Scholar
• Clarke DF, Wong RJ, Wenning L, et al. Raltegravir in vitro effect on bilirubin binding. Pediatr Infect Dis J. 2013 Sep;32(9):978–980. PubMed PMID: 23470680; PubMed Central PMCID: PMC3856729. eng. DOI:10.1097/INF.0b013e31829044a8
   PubMed Web of Science ®Google Scholar
• Lommerse J, Clarke D, Chain A, et al. Raltegravir dosing in neonates (IMPAACT P1110) - use of allometry and maturation in PK modeling to develop a daily dosing regimen for investigation during the first weeks of life. Population Approach Group Europe (PAGE) Conference; Hersonissos, Crete, Greece 2015.
   Google Scholar
• Clarke D, Acosta EP, Lommerse J, et al. and P1110 Protocol Team. Raltegravir (RAL) pharmacokinetics (PK) and safety in HIV-1 exposed neonates at high risk of infection (IMPAACT P1110). 8th International AIDS Conference; Vancouver, Canada, 2015.
   Google Scholar
• Clarke DF, Acosta EP, Cababasay M, et al. and P1110 Protocol Team. Raltegravir pharmacokinetics and safety in HIV-1 exposed neonates: dose-finding study. Conference on Retroviruses and Opportunistic Infections; Seattle, WA, 2017.
   Google Scholar
• Soriano V, Geretti AM, Perno CF, et al. Optimal use of maraviroc in clinical practice. Aids. 2008 Nov 12;22(17):2231–2240. PubMed PMID: 18981762; eng. DOI:10.1097/QAD.0b013e3283136d95
   PubMed Web of Science ®Google Scholar
• Maravirioc (Selezentry) [package insert]. Food and Drug Administration. 2016. [cited 2017 Oct 11]. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022128lbl.pdf.
   Google Scholar
• Dolutegravir [package insert]. Food and Drug Administration. 2016. [cited 2017 Oct 11]. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204790s001lbl.pdf.
   Google Scholar
• Mulligan N, Best BM, Capparelli E, et al. Dolutegravir pharmacokinetics in HIV-infected pregnant and postpartum women. 23rd Conference on Retroviruses and Opportunistic Infections; Boston, MA, 2016.
   Google Scholar
• Delaney AL. Arvedson JC. Development of swallowing and feeding: prenatal through first year of life [Review]. Dev Disabil Res Rev. 2008;142:105–117. PubMed PMID: 18646020; eng. . DOI: 10.1002/ddrr.16
   PubMed Web of Science ®Google Scholar
• Van Riet-Nales DA, Schobben AF, Vromans H, et al. Safe and effective pharmacotherapy in infants and preschool children: importance of formulation aspects [Review]. Arch Dis Child. 2016 Jul;101(7):662–669. PubMed PMID: 26979250; PubMed Central PMCID: PMC4941170. eng. DOI:10.1136/archdischild-2015-308227
   PubMed Web of Science ®Google Scholar
• Klingmann V, Seitz A, Meissner T, et al. Acceptability of uncoated mini-tablets in neonates–a randomized controlled trial [Randomized controlled trial]. J Pediatr. 2015 Oct;167(4):893–896 e2. PubMed PMID: 26259675; eng.
   PubMed Web of Science ®Google Scholar
• Teppler H, Thompson K, Chain A, et al. Crushing of raltegravir (RAL) chewable tablets for administration in infants and young children. International Workshop on HIV Pediatrics; 21–22 July 2017; Paris, France.
   Google Scholar